The LRB Team
An Expertise at the service of tomorrow’s nuclear medicine
The LRB research team (Inserm / Grenoble Alpes University) is a translational laboratory dedicated to the development of new radiopharmaceuticals for both diagnostic and therapeutic applications.
Located at the heart of Grenoble’s health campus, the team brings together researchers, physicians, pharmacists, biologists, and imaging specialists around a shared mission: to design, characterize, evaluate, and transfer novel radiolabeled compounds into clinical practice, addressing real medical needs.
Our vision: From the Clinic to the Clinic
Organized into two main hubs—a preclinical laboratory based at the Faculty of Medicine, and a clinical entity comprising practitioners from Grenoble Alpes University Hospital (CHUGA)—the team covers the entire life cycle of radiopharmaceutical development:
-
Selection of relevant biological targets
-
Chemical design and radiolabeling of compounds
-
Preclinical evaluation (in vitro / in vivo)
-
Clinical transfer and trial management (Phases I, II, III)
This integrated, rigorous, and collaborative approach enables the team to fully engage with the challenges of more personalized, predictive, and effective medicine, directly addressing clinical needs in oncology, cardiology, neurology, and metabolism.
With over 45 years of experience in translational research, the LRB has developed a unique expertise chain in France, supported by cutting-edge technological platforms: radiochemistry, preclinical imaging, pharmaceutical preparation, and clinical monitoring.
Beyond scientific innovation, every project pursued by the team has a clear goal: to improve patient care by providing nuclear medicine with more effective, targeted, and safer diagnostic and therapeutic tools.
Discover our page "Training through Research"
The LRB is certified to ISO 9001 and NF X 50-900 standards since 2020 for its quality management system, ensuring reliability and traceability in its research processes.
Introduction from Pr Catherine Ghezzi, director of LRB :
The "Laboratoire Radiopharmaceutiques Biocliniques” : From the Clinic to the Clinic.
Nuclear Medicine is a medical specialty based on the administration of radiolabeled compounds, called radiopharmaceuticals, which target specific biological markers or functions to diagnose, monitor, and treat a wide range of diseases.
The mission of the LRB team is to design and develop new radiopharmaceuticals to address unmet clinical needs in cardiology, oncology, neurodegenerative diseases, and metabolic diseases. Developing a novel radiopharmaceutical, like any other drug, is a long and complex process. Bringing a new compound into clinical practice, which is the ultimate goal of our translational research approach, first requires a clear and well-defined medical need.
Our multidisciplinary team brings together physicians, biologists, radiochemists, and radiopharmacists, enabling us to cover every stage of radiopharmaceutical development: from target selection, through all phases of preclinical research, to the transfer of selected molecules into Phase I, II, and III clinical trials.
With over forty-five years of experience in translational research, our team has established a unique recognized chain of expertise for the development of new radiopharmaceuticals. Each successful transfer of a novel molecule into clinical practice, by enabling improved patient care, strengthens the role of nuclear medicine as a key player in personalized medicine.
In addition to the team’s historic focus on radiopharmaceutical development and the optimization of existing radiopharmaceuticals, we have expanded our scope in recent years to include a new axis: the development of medical devices and imaging analysis tools in cardiology.
This third axis has been formalized through the long-standing scientific commitment of our hospital-university cardiologists, as well as our active participation in Grenoble’s health technology ecosystem. Our involvement in the LabEx GIMeD (Grenoble Initiative in Medical Devices), particularly through the coordination of the Imaging and Theranostics axis, reflects a strong and structuring local momentum for the future.
Pr. Catherine Ghezzi
LRB's 45th Anniversary Video (in French)